Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target.






